Basic | |
---|---|
Market Cap | £33.23B |
Price | £373.3 |
52 Week Range | 308.37-400.649 |
Beta | 0.24 |
Margins | |
Gross Profit Margin | 60.68% |
Operating Profit Margin | 17.82% |
Net Profit Margin | 9.66% |
Valuation (TTM) | |
P/E Ratio | 31.49 |
Price to Sales Ratio | 3.00 |
Price to Book Ratio | 2.06 |
PEG Ratio | 0.31 |
Drug Manufacturers - Specialty & Generic
Healthcare
25,408
2022-07-18T00:00:00.000Z
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.
44 1932 822000
Building 5, Weybridge, KT13 0NY, GB